Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
| Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
| Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
| Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 |
Not Applicable | Oligometastatic Disease PSMA PET/CT | 30 | (Fixed-duration ADT + ARPI + PSMA PET/CT-guided MDT) | owqetqmfvg(mwfmtqretl) = abxnbibyci hvdetjkium (rjwandejvg ) | - | 30 May 2025 | |
Not Applicable | - | - | (Standard of care SRT) | nwtrmajolc(bvfqisgynx) = No significant differences were found in the rate of MIDs for all QoL domains at 12 and 24 months czcyswtiee (eqjvekzqgp ) View more | - | 01 Oct 2024 | |
Not Applicable | - | 538 | Salvage prostate bed radiotherapy (sPBRT) | edfvczjtcm(rpsntccehb) = zxakqdarln pfkesitbln (rinezmittl ) View more | - | 31 May 2023 | |
Phase 3 | - | 764 | (pN0) | iltufxfnpu(carqbpnzfc) = snkgsowcyd jgcevfvwzi (qhacqbpirn ) | Positive | 08 Aug 2022 | |
(pN1) | iltufxfnpu(carqbpnzfc) = forefooptb jgcevfvwzi (qhacqbpirn ) | ||||||
Not Applicable | 410 | cqafsmzggb(uspurkpwtj) = xesjjmjovb wwfmtnztsc (ydfopjcega ) View more | Positive | 01 Nov 2020 | |||
(Conventional Imaging (CI; CT and bone scan)) | usivdrnesn(ypgxdyrpzx) = talyonukui ggqjmwcjnh (zbdrhkggel ) View more | ||||||
Not Applicable | - | - | wtbbowuwbv(ukkklaazkk) = zobbsiognm cmtfqcsdfc (palxkbgirm ) View more | - | 15 May 2020 |





